Next generation vaccines and vectors: Designing downstream processes for recombinant protein-based virus-like particles

Biotechnology Journal

Volumn 10, Issue 5, 2015, Pages 715-727

  Effio, Christopher Ladd ^a   Hubbuch, Jürgen ^a  

^a KARLSRUHE INSTITUTE OF TECHNOLOGY   (Germany)

Author keywords

High throughput screening; Modeling; Purification; Vaccine; VLP

Indexed keywords

COST REDUCTION; DIAGNOSIS; MODELS; PURIFICATION; VACCINES; VIRUSES;

DEVELOPMENT STRATEGIES; DOWNSTREAM-PROCESSING; HIGH THROUGHPUT SCREENING; MANUFACTURING PROCESS; PROCESS DEVELOPMENT; PURIFICATION PROCESS; VIRUS-LIKE PARTICLES; VLP;

RECOMBINANT PROTEINS;

MAGNETIC NANOPARTICLE; RECOMBINANT PROTEIN; VACCINE; VIRUS PROTEIN; VIRUS VECTOR; VIRUS LIKE PARTICLE VACCINE;

AFFINITY CHROMATOGRAPHY; DOWNSTREAM PROCESSING; EXPANDED BED ADSORPTION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; ION EXCHANGE CHROMATOGRAPHY; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; PROCESS DEVELOPMENT; PRODUCT RECOVERY; PURIFICATION; REVIEW; VIRUS LIKE AGENT; BIOSYNTHESIS; ECONOMICS; GENE VECTOR; HUMAN; IMMUNOLOGY; ISOLATION AND PURIFICATION; PHARMACEUTICS; PROCEDURES; TRENDS;

GENETIC VECTORS; HUMANS; RECOMBINANT PROTEINS; TECHNOLOGY, PHARMACEUTICAL; VACCINES, VIRUS-LIKE PARTICLE;

EID: 84928800935     PISSN: 18606768     EISSN: 18607314     Source Type: Journal    
DOI: 10.1002/biot.201400392     Document Type: Review

References (170)

1. Ludwig, C., Wagner, R., Virus-like particles-universal molecular toolboxes. Curr. Opin. Biotechnol. 2007, 18, 537-545.
2. Vekemans, J., Leach, A., Cohen, J., Development of the RTS, S/AS malaria candidate vaccine. Vaccine 2009, 27Suppl6, 67-71.
3. Rodríguez, D., González-Aseguinolaza, G., Rodríguez, J. R., Vijayan, A. et al., Vaccine efficacy against malaria by the combination of porcine parvovirus-like particles and vaccinia virus vectors expressing CS of Plasmodium. PLoS One 2012, 7, doi:10.1371/journal.pone.0034445.
4. Chuan, Y. P., Wibowo, N., Connors, N. K., Wu, Y. et al., Microbially synthesized modular virus-like particles and capsomeres displaying group A streptococcus hypervariable antigenic determinants. Biotechnol. Bioeng. 2014, 111, 1062-1070.
5. Chackerian, B., Virus-like particle based vaccines for Alzheimer disease. Hum. Vaccin. 2010, 6, 926-930.
6. Graf, A., Staufenbiel, M., Blaettler, T., Paganetti, P., Composition comprising vlp and amyloid beta peptide, US Patent 8617566, 2013.
7. Jin, H., Wang, W., Zhao, S., Yang, W. et al., Aβ-HBc virus-like particles immunization without additional adjuvant ameliorates the learning and memory and reduces Aβ deposit in PDAPP mice. Vaccine 2014, 32, 4450-4456.
8. Sharma, S., Whalley, A., McLaughli, J., Brello, F. et al., Fermentation process technology transfer for production of a recombinant vaccine component. BioPharm International 2011, 24, 30-39.
9. Brown, A., Champion, B., Christy, C., Gervais, D. et al., Ige ch3 peptide vaccine, US Patent 8475801, 2013.
10. Spohn, G., Schori, C., Keller, I., Sladko, K. et al., Preclinical efficacy and safety of an anti-IL-1β vaccine for the treatment of type 2 diabetes. Mol. Ther. Methods Clin. Dev. 2014, 1, doi:10.1038/mtm.2014.48.
11. Klamp, T., Schumacher, J., Huber, G., Kühne, C. et al., Highly specific auto-antibodies against claudin-18 isoform 2 induced by a chimeric HBcAg virus-like particle vaccine kill tumor cells and inhibit the growth of lung metastases. Cancer Res. 2011, 71, 516-527.
12. Sheen, M. R., Lizotte, P. H., Toraya-Brown, S., Fiering, S., Stimulating antitumor immunity with nanoparticles. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 2014, 6, 496-505.
13. Zochowska, M., Piguet, A.-C., Jemielity, J., Kowalska, J. et al., Virus-like particle-mediated intracellular delivery of mRNA cap analog with in vivo activity against hepatocellular carcinoma. Nanomedicine 2014, 11, 67-76.
14. Bachmann, M. F., Whitehead, P., Active immunotherapy for chronic diseases. Vaccine 2013, 31, 1777-1784.
15. Vicente, T., Roldão, A., Peixoto, C., Carrondo, M. J. T., Alves, P. M., Large-scale production and purification of VLP-based vaccines. J. Invertebr. Pathol. 2011, 107, S42-48.
16. Roldão, A., Silva, A. C., Mellado, M. C. M., Tecnologia, I. D., Lisboa, U. N. D., 1. Viruses and virus-like particles in biotechnology: Fundamentals and applications, in: Moo-Young, M. (Ed.), Comprehensive Biotechnology, Elsevier B.V., 2011.
17. Kushnir, N., Streatfield, S. J., Yusibov, V., Virus-like particles as a highly efficient vaccine platform: diversity of targets and production systems and advances in clinical development. Vaccine 2012, 31, 58-83.
18. Pushko, P., Pumpens, P., Grens, E., Development of virus-like particle technology from small highly symmetric to large complex virus-like particle structures. Intervirology 2013, 56, 141-165.
19. Zeltins, A., Construction and characterization of virus-like particles: a review. Mol. Biotechnol. 2013, 53, 92-107.
20. Lua, L. H. L., Connors, N. K., Sainsbury, F., Chuan, Y. P. et al., Bioengineering virus-like particles as vaccines. Biotechnol. Bioeng. 2014, 111, 425-440.
21. Brisson, M., Drolet, M., Malagón, T., Inequalities in human papillomavirus (HPV)-associated cancers: implications for the success of HPV vaccination. J. Natl. Cancer Inst. 2013, 105, 158-161.
22. Harrison, C., Britt, H., Garland, S., Conway, L. et al., Decreased management of genital warts in young women in australian general practice post introduction of national HPV vaccination program: Results from a nationally representative cross-sectional general practice study. PLoS One 2014, 9, doi:10.1371/journal.pone.0105967.
23. Wilson, M. F., Blum, R., Dandona, P., Mousa, S. A., Effects in humans of intravenously administered endotoxin on soluble cell-adhesion molecule and inflammatory markers: a model of human diseases. Clin. Exp. Pharmacol. Physiol. 2001, 28, 376-380.
24. Duchene, M., Descamps, J., Pierard, I., Immunogenicity of impurities in cell-derived vaccines, in: Stacey, G., Davis, J. (Eds.) Medicines from Animal Cell Culture, John Wiley & Sons, Weinheim 2007, pp. 491-496.
25. Bernstein, D. I., El Sahly, H. M., Keitel, W. A., Wolff, M. et al., Safety and immunogenicity of a candidate parvovirus B19 vaccine. Vaccine 2011, 29, 7357-7363.
26. U.S. Food and Drug Administration, CBER, Guidance for Industry Information and Establishment Description Information for a Vaccine, 1999.
27. World Health Organization, Guidelines to assure the quality, safety and efficacy of recombinant human papillomavirus virus-like particle vaccines, 2006, 23-27.
28. World Health Organization, Guidelines on the quality, safety and efficacy of recombinant malaria vaccines targeting the pre-erythrocytic and blood stages of Plasmodium falciparum, 2014.
29. U.S. Food and Drug Administration, CBER, FDA Guidance for Industry Characterization and Qualification of Cell Substrates and Other Guidance for Industry Characterization and Qualification of Cell Substrates and Other Biological Materials Used in the Production of Viral Vaccines for Infectious Disease Indications, 2007.
30. RTS, S. Clinical Trials Partnership, Efficacy and safety of the RTS, S/AS01 malaria vaccine during 18 months after vaccination: A phase 3 randomized, controlled trial in children and young infants at 11 African sites. PLoS Med. 2014, 11, doi:10.1371/journal.pmed.1001685.
31. Brito, L. A., Singh, M., Acceptable levels of endotoxin in vaccine formulations during preclinical research. J. Pharm. Sci. 2011, 100, 34-3.
32. Cook, J. C., Joyce, J. G., George, H. A., Schultz, L. D. et al., Purification of virus-like particles of recombinant human papillomavirus type 11 major capsid protein L1 from Saccharomyces cerevisiae, Protein Expr. Purif. 1999, 17, 477-484.
33. Wolter, T., Richter, A., Assays for controlling host-cell impurities in biopharmaceuticals. Bioprocess Int. 2005, 2, 40-46.
34. Mach, H., Volkin, D. B., Troutman, R. D., Wang, B. E. I., Disassembly and reassembly of yeast-derived recombinant human papillomavirus virus-like particles ( HPV VLPs ), J. Pharm. Sci. 2006, 95, 2195-2206.
35. McCarthy, M. P. M. C., White, W. I., Palmer-Hill, F., Koenig, S., Suzich, J. A., Quantitative disassembly and reassembly of human papillomavirus type 11 viruslike particles in vitro. J. Virol. 1998, 72, 32-41.
36. Ren, Y., Wong, S.-M., Lim, L.-Y., In vitro-reassembled plant virus-like particles for loading of polyacids. J. Gen. Virol. 2006, 87, 2749-2754.
37. Xing, L., Li, T.-C., Mayazaki, N., Simon, M. N. et al., Structure of hepatitis E virion-sized particle reveals an RNA-dependent viral assembly pathway. J. Biol. Chem. 2010, 285, 33175-33183.
38. Link, A., Zabel, F., Schnetzler, Y., Titz, A. et al., Innate immunity mediates follicular transport of particulate but not soluble protein antigen. J. Immunol. 2012, 188, 3724-3733.
39. Roldão, A., Mellado, M. C. M., Lima, J. C., Carrondo, M. J. T. et al., On the effect of thermodynamic equilibrium on the assembly efficiency of complex multi-layered virus-like particles (VLP): The case of rotavirus VLP. PLoS Comput. Biol. 2012, 8, doi:10.1371/journal.pcbi.1002367.
40. Zhao, Q., Allen, M. J., Wang, Y., Wang, B. et al., Disassembly and reassembly improves morphology and thermal stability of human papillomavirus type 16 virus-like particles. Nanomedicine 2012, 8, 1182-1189.
41. Zhao, Q., Modis, Y., High, K., Towne, V. et al., Disassembly and reassembly of human papillomavirus virus-like particles produces more virion-like antibody reactivity. Virol. J. 2012, 9, doi:10.1186/1743-422X-9-5.
42. Zhang, L., Tang, R., Bai, S., Connors, N. K. et al., Molecular energetics in the capsomere of virus-like particle revealed by molecular dynamics simulations. J. Phys. Chem. B 2013, 117, 5411-5421.
43. Zhang, L., Tang, R., Bai, S., Connors, N. K. et al., Energetic changes caused by antigenic module insertion in a virus-like particle revealed by experiment and molecular dynamics simulations. PLoS One 2014, 9, doi:10.1371/journal.pone.0107313.
44. Shi, L., Sanyal, G., Ni, A., Luo, Z. et al., Stabilization of human papillomavirus virus-like particles by non-ionic surfactants. J. Pharm. Sci. 2005, 94, 1538-1551.
45. Ding, Y., Chuan, Y. P., He, L., Middelberg, A. P. J., Modeling the competition between aggregation and self-assembly during virus-like particle processing. Biotechnol. Bioeng. 2010, 107, 550-560.
46. Sánchez-Rodríguez, S. P., Münch-Anguiano, L., Echeverría, O., Vázquez-Nin, G. et al., Human parvovirus B19 virus-like particles: In vitro assembly and stability. Biochimie 2012, 94, 870-878.
47. Tsoka, S., Ciniawskyj, O. C., Thomas, O. R., Titchener-Hooker, N. J. et al., Selective flocculation and precipitation for the improvement of virus-like particle recovery from yeast homogenate. Biotechnol. Prog. 2000, 16, 661-667.
48. Jiang, Z., Tong, G., Cai, B., Xu, Y., Lou, J., Purification and immunogenicity study of human papillomavirus 58 virus-like particles expressed in Pichia pastoris, Protein Expr. Purif. 2011, 80, 203-210.
49. Lünsdorf, H., Gurramkonda, C., Adnan, A., Khanna, N., Rinas, U., Virus-like particle production with yeast: ultrastructural and immunocytochemical insights into Pichia pastoris producing high levels of the hepatitis B surface antigen. Microb. Cell Fact. 2011, 10, doi:10.1186/1475-2859-10-48.
50. Iammarino, M., Nti-gyabaah, J., Chandler, M., Roush, D., Göklen, K., Impact of cell density and viability on primary clarification of mammalian cell broth. Bioprocess Int. 2007, 11, 38-50.
51. Negrete, A., Pai, A., Shiloach, J., Use of hollow fiber tangential flow filtration for the recovery and concentration of HIV virus-like particles produced in insect cells. J. Virol. Methods 2014, 195, 240-246.
52. Cruz, P. E., Peixoto, C. C., Devos, K., Moreira, L. et al., Characterization and downstream processing of HIV-1 core and virus-like-particles produced in serum free medium. Enzyme Microb. Technol. 2000, 26, 61-70.
53. Peixoto, C., Sousa, M. F. Q., Silva, A. C., Carrondo, M. J. T., Alves, P. M., Downstream processing of triple layered rotavirus like particles. J. Biotechnol. 2007, 127, 452-461.
54. Yigzaw, Y., Piper, R., Tran, M., Shukla, A. A., Exploitation of the adsorptive properties of depth filters for host cell protein removal during monoclonal antibody purification. Biotechnol. Prog. 2006, 22, 288-296.
55. Schirmer, E. B., Kuczewski, M., Golden, K., Lain, B. et al., Primary clarification of very high-density cell culture harvests by enhanced cell settling. Bioprocess. Int. 2010, 1, 32-39.
56. Jaffrin, M. Y., Dynamic filtration with rotating disks, and rotating and vibrating membranes: an update. Curr. Opin. Chem. Eng. 2012, 1, 171-177.
57. Vicente, T., Sousa, M. F., Peixoto, C., Mota, J. P. et al., Anion-exchange membrane chromatography for purification of rotavirus-like particles. J. Memb. Sci. 2008, 311, 270-283.
58. Vicente, T., Burri, S., Wellnitz, S., Walsh, K. et al., Fully aseptic single-use cross flow filtration system for clarification and concentration of cytomegalovirus-like particles. Eng. Life Sci. 2014, 14, 318-326.
59. Chung, C.-Y., Chen, C.-Y., Lin, S.-Y., Chung, Y.-C. et al., Enterovirus 71 virus-like particle vaccine: improved production conditions for enhanced yield. Vaccine 2010, 28, 6951-6957.
60. Shukla, A. A., Etzel, M. R., Gadam, S., Process Scale Bioseparations for the Biopharmaceutical Industry, Taylor & Francis Group, Boca Raton 2007.
61. Juckes, I. R. M., Town, C., Fractionation of proteins and viruses with polyethylene glycol. Biochim. Biophys. Acta 1971, 229, 535-546.
62. Summa, M., von Bonsdorff, C.-H., Maunula, L., Evaluation of four virus recovery methods for detecting noroviruses on fresh lettuce, sliced ham, and frozen raspberries. J. Virol. Methods 2012, 183, 154-160.
63. Kattur Venkatachalam, A. R., Szyporta, M., Kiener, T. K., Balraj, P., Kwang, J., Concentration and purification of enterovirus 71 using a weak anion-exchange monolithic column. Virol. J. 2014, 11, doi:10.1186/1743-422X-11-99.
64. Phelps, J. P., Dang, N., Rasochova, L., Inactivation and purification of cowpea mosaic virus-like particles displaying peptide antigens from Bacillus anthracis, J. Virol. Methods 2007, 141, 146-153.
65. Koho, T., Mäntylä, T., Laurinmäki, P., Huhti, L. et al., Purification of norovirus-like particles (VLPs) by ion exchange chromatography. J. Virol. Methods 2012, 181, 6-11.
66. Metz, S. W., Gardner, J., Geertsema, C., Le, T. T. et al., Effective chikungunya virus-like particle vaccine produced in insect cells. PLoS Negl. Trop. Dis. 2013, 7, doi: 10.1371/journal.pntd.0002124.
67. Matheus, S., Friess, W., Schwartz, D., Mahler, H.-C., Liquid high concentration IgG1 antibody formulations by precipitation. J. Pharm. Sci. 2009, 98, 3043-3057.
68. Knevelman, C., Davies, J., Allen, L., Titchener-Hooker, N. J., High-throughput screening techniques for rapid peg-based precipitation of igg4 mab from clarified cell culture supernatant. Biotechnol. Prog. 2010, 26, 697-705.
69. Sommer, R., Tscheliessnig, A., Satzer, P., Schulz, H. et al. Capture and intermediate purification of recombinant antibodies with combined precipitation methods. Biochem. Eng. J. 2015, 93, 200-211.
70. Kuczewski, M., Schirmer, E., Lain, B., Zarbis-Papastoitsis, G., A single-use purification process for the production of a monoclonal antibody produced in a PER.C6 human cell line. Biotechnol. J. 2011, 6, 56-65.
71. Oelmeier, S., Ladd-Effio, C., Hubbuch, J., Alternative separation steps for monoclonal antibody purification: Combination of centrifugal partitioning chromatography and precipitation. J. Chromatogr. A 2013, 1319, 118-126.
72. Atha, D. H., Inghamg, K. C., Mechanism of precipitation of proteins by polyethylene glycols. J. Biol. Chem. 1981, 256, 12108-12117.
73. Odijk, T., Depletion theory and the precipitation of protein by polymer. J. Phys. Chem. B 2009, 113, 3941-3946.
74. Sim, S.-L., He, T., Tscheliessnig, A., Mueller, M. et al., Protein precipitation by polyethylene glycol: A generalized model based on hydrodynamic radius. J. Biotechnol. 2012, 157, 315-319.
75. Lis, J. T., Schleif, R., Size fractionation of double-stranded DNA by precipitation with polyethylene glycol. Nucleic Acids Res. 1975, 2, 383-389.
76. Jungbauer, A., Hahn, R., Polymethacrylate monoliths for preparative and industrial separation of biomolecular assemblies. J. Chromatogr. A 2008, 1184, 62-79.
77. Qu, J.-B., Wan, X.-Z., Zhai, Y.-Q., Zhou, W.-Q. et al., A novel stationary phase derivatized from hydrophilic gigaporous polystyrene-based microspheres for high-speed protein chromatography. J. Chromatogr. A 2009, 1216, 6511-6516.
78. Thomas, H., Coquebert de Neuville, B., Storti, G., Morbidelli, M. et al., Role of tentacles and protein loading on pore accessibility and mass transfer in cation exchange materials for proteins. J. Chromatogr. A 2013, 1285, 48-56.
79. Orr, V., Zhong, L., Moo-Young, M., Chou, C. P., Recent advances in bioprocessing application of membrane chromatography. Biotechnol. Adv. 2013, 31, 450-465.
80. Michel, P. O., Mäkelä, A. R., Korhonen, E., Toivola, J. et al., Purification and analysis of polyhistidine-tagged human parvovirus B19 VP1 and VP2 expressed in insect cells. J. Virol. Methods 2008, 152, 1-5.
81. Lipin, D. I., Raj, A., Lua, L. H. L., Middelberg, A. P. J., Affinity purification of viral protein having heterogeneous quaternary structure: modeling the impact of soluble aggregates on chromatographic performance. J. Chromatogr. A 2009, 1216, 5696-5708.
82. Nishimura, Y., Takeda, K., Ishii, J., Ogino, C., Kondo, A., An affinity chromatography method used to purify His-tag-displaying bio-nanocapsules. J. Virol. Methods 2013, 189, 393-396.
83. Ohtaki, N., Takahashi, H., Kaneko, K., Gomi, Y. et al., Purification and concentration of non-infectious West Nile virus-like particles and infectious virions using a pseudo-affinity cellufine sulfate column. J. Virol. Methods 2011, 174, 131-135.
84. Kim, H. J., Lim, S. J., Kwag, H.-L., Kim, H.-J., The choice of resin-bound ligand affects the structure and immunogenicity of column-purified human papillomavirus type 16 virus-like particles. PLoS One 2012, 7, doi: 10.1371/journal.pone.0035893.
85. Choi, Y. R., Kim, H. J., Lee, J. Y., Kang, H. A., Kim, H.-J., Chromatographically-purified capsid proteins of red-spotted grouper nervous necrosis virus expressed in Saccharomyces cerevisiae form virus-like particles. Protein Expr. Purif. 2013, 89, 162-168.
86. Guo, P., El-Gohary, Y., Prasadan, K., Shiota, C. et al., Rapid and simplified purification of recombinant adeno-associated virus. J. Virol. Methods 2012, 183, 139-146.
87. Zhou, W., Bi, J., Janson, J.-C., Dong, A. et al., Ion-exchange chromatography of hepatitis B virus surface antigen from a recombinant Chinese hamster ovary cell line. J. Chromatogr. A 2005, 1095, 119-125.
88. Urbas, L., Jarc, B. L., Barut, M., Zochowska, M. et al., Purification of recombinant adenovirus type 3 dodecahedric virus-like particles for biomedical applications using short monolithic columns. J. Chromatogr. A 2011, 1218, 2451-2459.
89. Tomé-Amat, J., Fleischer, L., Parker, S. A., Bardliving, C., Batt, C., Secreted production of assembled Norovirus virus-like particles from Pichia pastoris. Microb. Cell Fact. 2014, 13, doi: 10.1186/s12934-014-0134-z.
90. Chandramouli, S., Medina-Selby, A., Coit, D., Schaefer, M. et al., Generation of a parvovirus B19 vaccine candidate. Vaccine 2013, 31, 3872-3878.
91. Wenger, M. D., Dephillips, P., Price, C. E., Bracewell, C. E., An automated microscale chromatographic purification of virus-like particles as a strategy for process development. Biotechnol. Appl. Biochem. 2007, 47, 131-139.
92. Gagnon, P., Godfrey, B., Ladd, D., Method for obtaining unique selectivities in ion-exchange chromatography by addition of organic polymers to the mobile phase. J. Chromatogr. A 1996, 743, 51-55.
93. Snyder, M. A., Ng, P., Mekosh, H., Gagnon, P., PEG enhances viral clearance on ceramic hydroxyapatite. J. Sep. Sci. 2009, 32, 4048-4051.
94. Lee, J., Gan, H. T., Latiff, S. M. A., Chuah, C. et al., Principles and applications of steric exclusion chromatography. J. Chromatogr. A 2012, 1270, 162-170.
95. Gagnon, P., Toh, P., Lee, J., High productivity purification of immunoglobulin G monoclonal antibodies on starch-coated magnetic nanoparticles by steric exclusion of polyethylene glycol. J. Chromatogr. A 2014, 1324, 171-80.
96. Oehme, F., Peters, J., Mixed-mode chromatography in downstream process development. BioPharm. Int. 2010.
97. Burden, C. S., Jin, J., Podgornik, A., Bracewell, D. G., A monolith purification process for virus-like particles from yeast homogenate. J. Chromatogr. B 2012, 880, 82-89.
98. Rosa, P. A. J., Ferreira, I. F., Azevedo, A. M., Aires-Barros, M. R., Aqueous two-phase systems: A viable platform in the manufacturing of biopharmaceuticals. J. Chromatogr. A 2010, 1217), 2296-2305.
99. Benavides, J., Rito-Palomares, M., Asenjo, J. A., Aqueous two-phase systems. Comprehensive Biotechnology, Elsevier B.V., 2011, doi:10.1016/B978-0-08-088504-9.00124-0.
100. Wiendahl, M., Oelmeier, S. A., Dismer, F., Hubbuch, J., High-throughput screening-based selection and scale-up of aqueous two-phase systems for pDNA purification. J. Sep. Sci. 2012, 35, 3197-3207.
101. Muendges, J., Stark, I., Mohammad, S., Górak, A., Zeiner, T., Fluid phase equilibria single stage aqueous two-phase extraction for monoclonal antibody purification from cell supernatant. Fluid Phase Equilib. 2015, 385, 227-236.
102. Eggersgluess, J. K., Richter, M., Dieterle, M., Strube, J., Multi-stage aqueous two-phase extraction for the purification of monoclonal antibodies. Chem. Eng. Technol. 2014, 37, 675-682.
103. Rosa, P. A. J., Azevedo, A. M., Sommerfeld, S., Bäcker, W., Aires-Barros, M. R., Continuous aqueous two-phase extraction of human antibodies using a packed column. J. Chromatogr. B. Analyt. Technol. Biomed. Life Sci. 2012, 880, 148-156.
104. Sutherland, I., Hewitson, P., Siebers, R., van den Heuvel, R. et al., Scale-up of protein purifications using aqueous two-phase systems: Comparing multilayer toroidal coil chromatography with centrifugal partition chromatography. J. Chromatogr. A 2011, 1218, 5527-5530.
105. Silva, D. F. C., Azevedo, A. M., Fernandes, P., Chu, V. et al., Design of a microfluidic platform for monoclonal antibody extraction using an aqueous two-phase system. J. Chromatogr. A 2012, 1249, 1-7.
106. Schügerl, K., Hubbuch, J., Integrated bioprocesses. Curr. Opin. Microbiol. 2005, 8, 294-300.
107. Diederich, P., Amrhein, S., Hämmerling, F., Hubbuch, J., Evaluation of PEG/phosphate aqueous two-phase systems for the purification of the chicken egg white protein avidin by using high-throughput techniques. Chem. Eng. Sci. 2013, 104, 945-956.
108. Benavides, J., Mena, J. A., Cisneros-Ruiz, M., Ramírez, O. T. et al., Rotavirus-like particles primary recovery from insect cells in aqueous two-phase systems. J. Chromatogr. B. Analyt. Technol. Biomed. Life Sci. 2006, 842, 48-57.
109. Luechau, F., Ling, T. C., Lyddiatt, A., Recovery of B19 virus-like particles by aqueous two-phase systems. Food Bioprod. Process. 2011, 89, 322-327.
110. Rito-Palomares, Middelberg, A. P., Aqueous two-phase systems for the recovery of a recombinant viral coat protein from Escherichia coli. J. Chem. Technol. Biotechnol. 2002, 77, 1025-1029.
111. Arpanaei, A., Heebøll Nielsen, A., Hubbuch, J. J., Thomas, O. R. T., Hobley, T. J., Critical evaluation and comparison of fluid distribution systems for industrial scale expanded bed adsorption chromatography columns., J. Chromatogr. A 2008, 1198-1199, 131-139.
112. Ng, M. Y. T., Tan, W. S., Abdullah, N., Ling, T. C., Tey, B. T., Effect of different operating modes and biomass concentrations on the recovery of recombinant hepatitis B core antigen from thermal-treated unclarified Escherichia coli feedstock. J. Biotechnol. 2008, 138, 74-79.
113. Yap, W. B., Tey, B. T., Alitheen, N. B. M., Tan, W. S., Purification of His-tagged hepatitis B core antigen from unclarified bacterial homogenate using immobilized metal affinity-expanded bed adsorption chromatography. J. Chromatogr. A 2010, 1217, 3473-3480.
114. Cabrera, R., Lihme, A., Oishi, K., Vaarst, I., Methods for capturing virus like particles from plants using expanded bed chromatogrpahy US Patent App. PCT/EP2011/068, 919, 2012.
115. Pincus, S., Boddapati, S., Li, J., Sadowski, T., Release and stability testing programs for a novel virus-like particle vaccine. BioPharm. Int. 2010.
116. GE Healthcare, Removal of DNA and baculovirus from influenza virus-like particles using Capto™ Q. BioPharm. Int. 2011.
117. Iyer, G., Ramaswamy, S., Asher, D., Mehta, U. et al., Reduced surface area chromatography for flow-through purification of viruses and virus like particles. J. Chromatogr. A 2011, 1218, 3973-3981.
118. Iyer, G., Ramaswamy, S., Cheng, K.-S., Sisowath, N. et al., Flow-through purification of viruses - a novel approach to vaccine purification. Procedia Vaccinol. 2012, 6, 106-112.
119. Koho, T., Koivunen, M. R. L., Oikarinen, S., Kummola, L. et al., Coxsackievirus B3 VLPs purified by ion exchange chromatography elicit strong immune responses in mice. Antiviral Res. 2014, 104, 93-101.
120. Kim, H. J., Kim, S. Y., Lim, S. J., Kim, J. Y. et al., One-step chromatographic purification of human papillomavirus type 16 L1 protein from Saccharomyces cerevisiae. Protein Expr. Purif. 2010, 70, 68-74.
121. Cook III, J. C., Process for purifying human papillomavirus virus-like particles, US Patent 6602697, 2003.
122. Schmoeger, E., Paril, C., Tscheliessnig, R., Jungbauer, A., Adsorption of plasmid DNA on ceramic hydroxyapatite chromatographic materials. J. Sep. Sci. 2010, 33, 3125-3136.
123. Wagner, J. M., Pajerowski, J. D., Daniels, C. L., McHugh, P. M. et al., Enhanced production of Chikungunya virus-like particles using a high-pH adapted Spodoptera frugiperda insect cell line. PLoS One 2014, 9, doi: 10.1371/journal.pone.0094401.
124. Bundy, B. C., Swartz, J. R., Efficient disulfide bond formation in virus-like particles. J. Biotechnol. 2011, 154, 230-239.
125. Mukherjee, S., Thorsteinsson, M. V., Johnston, L. B., DePhillips, P. A., Zlotnick, A., A quantitative description of in vitro assembly of human papillomavirus 16 virus-like particles. J. Mol. Biol. 2008, 381, 229-237.
126. Liew, M. W. O., Chuan, Y. P., Middelberg, A. P. J., Reactive diafiltration for assembly and formulation of virus-like particles. Biochem. Eng. J. 2012, 68, 120-128.
127. Jain, N. K. Sahni, N., Kumru, O. S., Joshi, S. B. et al., Formulation and stabilization of recombinant protein based virus-like particle vaccines. Adv. Drug Deliv. Rev. 2014, doi: 10.1016/j.addr2014.10.023.
128. Quan, F.-S., Kim, M.-C., Lee, B.-J., Song, J.-M. et al., Influenza M1 VLPs containing neuraminidase induce heterosubtypic cross-protection. Virology 2012, 430, 127-135.
129. Rathore, A. S., Winkle, H., Quality by design for biopharmaceuticals. Nat. Biotechnol. 2009, 27, 26-37.
130. Yu, Z., Reid, J. C., Yang, Y.-P., Utilizing dynamic light scattering as a process analytical technology for protein folding and aggregation monitoring in vaccine manufacturing. J. Pharm. Sci. 2013, 102, 4284-4290.
131. Brooks, C. A., Cramer, S. M., Steric mass-action ion exchange: Displacement profiles and induced salt gradients. AIChE J. 1992, 38, 1969-1978.
132. Hahn, T., Sommer, A., Osberghaus, A., Heuveline, V., Hubbuch, J., Adjoint-based estimation and optimization for column liquid chromatography models. Comput. Chem. Eng. 2014, 64, 41-54.
133. Huuk, T. C., Hahn, T., Osberghaus, A., Hubbuch, J., Model-based integrated optimization and evaluation of a multi-step ion exchange chromatography. Sep. Purif. Technol. 2014, 136, 207-222.
134. Bensch, M., Schulze Wierling, P., von Lieres, E., Hubbuch, J., High throughput screening of chromatographic phases for rapid process development. Chem. Eng. Technol. 2005, 28, 1274-1284.
135. Wiendahl, M., Schulze Wierling, P., Nielsen, J., Fomsgaard Christensen, D. et al., High throughput screening for the design and optimization of chromatographic processes - miniaturization, automation and parallelization of breakthrough and elution studies. Chem. Eng. Technol. 2008, 31, 893-903.
136. Oelmeier, S. A., Ladd Effio, C., Hubbuch, J., High throughput screening based selection of phases for aqueous two-phase system-centrifugal partitioning chromatography of monoclonal antibodies. J. Chromatogr. A 2012, 1252, 104-114.
137. Wu, Y., Simons, J., Hooson, S., Abraham, D., Carta, G., Protein and virus-like particle adsorption on perfusion chromatography media. J. Chromatogr. A 2013, 1297, 96-105.
138. Pease, L. F., Lipin, D. I., Tsai, D.-H., Zachariah, M. R. et al., Quantitative characterization of virus-like particles by asymmetrical flow field flow fractionation, electrospray differential mobility analysis, and transmission electron microscopy. Biotechnol. Bioeng. 2009, 102, 845-855.
139. Mohr, J., Chuan, M. R., Wu, Y., Lua, L. H. L., Middelberg, A. P. J., Virus-like particle formulation optimization by miniaturized high-throughput screening. Methods 2013, 60, 248-256.
140. Shoemaker, G. K., van Duijn, E., Crawford, S. E., Uetrecht, C. et al., Norwalk virus assembly and stability monitored by mass spectrometry. Mol. Cell. Proteomics 2010, 9, 1742-1751.
141. Uetrecht, C., Barbu, I. M., Shoemaker, G. K., van Duijn, E., Heck, A. J. R., Interrogating viral capsid assembly with ion mobility-mass spectrometry. Nat. Chem. 2011, 3, 126-132.
142. Ladd Effio, C., Hubbuch, J., Virus-like particle and nano-particle vaccines 2014 - session 10 technology. Hum. Vaccin. Immunother. 2014, 10, doi: 10.4161/hv.29840.
143. Heider, S., Metzner, C., Quantitative real-time single particle analysis of virions. Virology 2014, 462-463, 199-206.
144. Brestrich, N., Briskot, T., Osberghaus, A., Hubbuch, J., A tool for selective inline quantification of co-eluting proteins in chromatography using spectral analysis and partial least squares regression. Biotechnol. Bioeng. 2014, 111, 1365-1373.
145. Hahn, B. T. J., Courbron, D., Hamer, M., Masoud, M. et al., Rapid manufacture and release of a GMP batch of avian influenza A(H7N9) virus-like particle vaccine made using recombinant baculovirus-Sf9 insect cell culture technology. Bioprocess. J. 2013, 12, 1-10.
146. Kröber, T., Wolff, M. W., Hundt, B., Seidel-Morgenstern, A., Reichl, U., Continuous purification of influenza virus using simulated moving bed chromatography. J. Chromatogr. A 2013, 1307, 99-110.
147. Nestola, P., Silva, R. J. S., Peixoto, C., Alves, P. M. et al., Adenovirus purification by two-column, size-exclusion, simulated countercurrent chromatography. J. Chromatogr. A 2014, 1347, 111-121.
148. Metz, S. W., Martina, B. E., van den Doel, P., Geertsema, C. et al., Chikungunya virus-like particles are more immunogenic in a lethal AG129 mouse model compared to glycoprotein E1 or E2 subunits. Vaccine 2013, 31, 6092-6096.
149. Schmitz, J., Roehrig, J., Barrett, A., Hombach, J., Next generation dengue vaccines: a review of candidates in preclinical development. Vaccine 2011, 29, 7276-7284.
150. Ku, Z., Liu, Q., Ye, X., Cai, Y. et al., A virus-like particle based bivalent vaccine confers dual protection against enterovirus 71 and coxsackievirus A16 infections in mice. Vaccine 2014, 32, 4296-4303.
151. Buonaguro, L., Tagliamonte, M., Visciano, M. L., Andersen, H. et al., Immunogenicity of HIV virus-like particles in rhesus macaques by intranasal administration. Clin. Vaccine Immunol. 2012, 19, 970-973.
152. Gissmann, L., HPV vaccines: preclinical development. Arch. Med. Res. 2009, 40, 466-470.
153. Li, T., Lin, H., Zhang, Y., Li, M. et al., Improved characteristics and protective efficacy in an animal model of E. coli-derived recombinant double-layered rotavirus virus-like particles. Vaccine 2014, 32, 1921-1931.
154. Chang, L.-J., Dowd, K. A., Mendoza, F. H., Saunders, J. G. et al., Safety and tolerability of chikungunya virus-like particle vaccine in healthy adults: a phase 1 dose-escalation trial. Lancet 2014, 6736, 25-27.
155. Mohammadi, D., International community ramps up Ebola vaccine effort. Lancet 2014, 384, 1658-1659.
156. Low, J. G. H., Lee, L. S., Ooi, E. E., Ethirajulu, K. et al., Safety and immunogenicity of a virus-like particle pandemic influenza A (H1N1) 2009 vaccine: Results from a double-blinded, randomized Phase I clinical trial in healthy Asian volunteers. Vaccine 2014, 32, 5041-5048.
157. Ward, B. J., Landry, N., Trépanier, S., Mercier, G. et al., Human antibody response to N-glycans present on plant-made influenza virus-like particle (VLP) vaccines. Vaccine 2014, 32, 6098-6106.
158. Fries, L. F., Smith, G. E., Glenn, G. M., A recombinant viruslike particle influenza a (h7n9) vaccine. N. Engl. J. Med. 2013, 369, 2564-2566.
159. Glenn, G. M., Smith, G., Fries, L., Raghunandan, R. et al., Safety and immunogenicity of a Sf9 insect cell-derived respiratory syncytial virus fusion protein nanoparticle vaccine. Vaccine 2013, 31, 524-532.
160. Riviere, M.-E., Caputo, A., Laurent, N., Vostiar, I. et al., Active Ab Immunotherapy Cad106 Phase Ii Dose-Adjuvant Finding Study: Immune Response. Alzheimer's Dement. 2014, 10, 447-448.
161. Caputo, A., Graf, A., Riviere, M.-E., Alva, G. et al., Active Ab Immunotherapy Cad106 Phase Ii Dose-Adjuvant Finding Study: Amyloid Pet. Alzheimer's Dement. 2014, 10, 445-446.
162. López-Macías, C., Ferat-Osorio, E., Tenorio-Calvo, T., Isibasi, A., Safety and immunogenicity of a virus-like particle pandemic influenza A (H1N1) 2009 vaccine in a blinded, randomized, placebo-controlled trial of adults in Mexico. Vaccine 2011, 29, 7826-7834.
163. Sundararajan, A., Sangster, M. Y., Frey, S., Atmar, R. L. et al., Robust mucosal-homing antibody-secreting B cell responses induced by intramuscular administration of adjuvanted bivalent human norovirus-like particle vaccine. Vaccine 2014, 33, 568-576.
164. Erickson, B. K., Landers, E. E., Huh, W. K., Update on vaccination clinical trials for HPV-related disease. Clin. Ther. 2014, 36, 8-16.
165. Hildesheim, A., Wacholder, S., Catteau, G., Struyf, F. et al., Efficacy of the HPV-16/18 vaccine: final according to protocol results from the blinded phase of the randomized Costa Rica HPV-16/18 vaccine trial. Vaccine 2014, 32, 5087-5097.
166. Umeh, R., Oguche, S., Oguonu, T., Pitmang, S. et al., Immunogenicity and safety of the candidate RTS, S/AS01 vaccine in young Nigerian children: A randomized, double-blind, lot-to-lot consistency trial. Vaccine 2014, 32, 6556-6562.
167. Dochez, C., Bogers, J. J., Verhelst, R., Rees, H., HPV vaccines to prevent cervical cancer and genital warts: An update Vaccine 2014, 32, 1595-1601.
168. Lacson, E., Teng, M., Ong, J., Vienneau, L. et al., Antibody response to Engerix-B® and Recombivax-HB® hepatitis B vaccination in end-stage renal disease. Hemodial. Int. 2005, 9, 367-375.
169. Zhang, X., Wei, M., Pan, H., Lin, Z. et al., Robust manufacturing and comprehensive characterization of recombinant hepatitis E virus-like particles in Hecolin®. Vaccine 2014, 32, 4039-4050.
170. Tan, Y. P., Ling, T. C., Tan, W. S., Yusoff, K., Tey, B. T., Purification of recombinant nucleocapsid protein of Newcastle disease virus from unclarified feedstock using expanded bed adsorption chromatography. Protein Expr. Purif. 2006, 46, 114-121.